Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.15B 16.05B 14.69B 27.57B 1,916B 27.94B 190B 73.95B 963B 75.2B 73.56B 3,184B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.5B 17.31B 15.84B 29.74B 2,066B 30.13B 205B 79.75B 1,038B 81.09B 79.33B 3,433B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+1.43%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 45.38
Extreme 45.38
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
108.99
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap.
23/3/26 Free

Head of Human Resources

329,891 0.1728%
23/3/26 Issuer sale

General Counsel

93,932 0.0492%
27/2/26 Fiscal year

Chief Executive Officer

168,201 0.0882%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+124.74%+27.46% 20.03B
+2.16%+5.05%+105.78%+303.57% 4.15B
-7.79%+18.77%+226.38%+31.80% 3.76B
+1.24%+2.57%+43.76%+63.68% 3.4B
+3.45%+7.26%+288.57%+463.92% 2.51B
-3.61%+3.84%-18.47%-20.90% 2.41B
-0.88%+16.87%+27.81% - 1.48B
+4.22%+51.58%+261.51%-17.56% 1.29B
-2.40%-5.13%+17.99%+39.91% 1B
-2.72%-2.82%-36.21%-1.66% 552M
Average -0.54%+10.09%+104.19%+98.91% 4.06B
Weighted average by Cap. +0.08%+5.38%+123.04%+83.84%

Financials

2024 2025
Net sales 2.76B 2.36B 2.21B 2.02B 3.8B 264B 3.85B 26.13B 10.19B 133B 10.36B 10.13B 439B 3.25B 2.78B 2.6B 2.38B 4.47B 311B 4.53B 30.75B 11.99B 156B 12.19B 11.93B 516B
Net income -1.03B -881M -825M -755M -1.42B -98.44B -1.44B -9.74B -3.8B -49.45B -3.86B -3.78B -164B -208M -178M -167M -153M -286M -19.9B -290M -1.97B -768M -9.99B -781M -764M -33.06B
Net Debt 1.74B 1.49B 1.39B 1.27B 2.39B 166B 2.42B 16.46B 6.42B 83.52B 6.52B 6.38B 276B 1.57B 1.34B 1.26B 1.15B 2.16B 150B 2.19B 14.87B 5.8B 75.47B 5.9B 5.77B 250B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock